Editorial

VHL gene mutation in patients with renal tumors

Volume 37 · Issue 3 Publish Date: July 25, 2019
Full Text PDF
Raşit Altıntaş
Bucak Devlet Hastanesi, Üroloji Kliniği, Burdur
Asude Alpman Durmaz
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
Burak Turna
Ege Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İzmir
Hüseyin Onay
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
Ferda Özkınay
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
İbrahim Kadri Cüreklibatır
Ege Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İzmir
Altıntaş, R., Durmaz, A. A., Turna, B., Onay, H., Özkınay, F., & Cüreklibatır, İbrahim K. (2019). VHL gene mutation in patients with renal tumors. Urology Research and Practice, 37(3), 191–197. Retrieved from https://urologyresearchandpractice.org/index.php/pub/article/view/2595
Full Text Full Text PDF

Abstract

Abstract

Objective: This study aimed to determine VHL gene mutations and the relation of these mutations to type and pathological stage of renal tumors.

Materials and methods: Forty patients (20 males, 20 females; mean age 59 years) who underwent ablative surgery for renal tumor prediagnosis between February 2009-November 2009 in of Ege University School of Medicine, Department of Urology were randomly selected. Twenty-nine of the patients underwent radical nephrectomy, 5 underwent partial nephrectomy, and 2 patients underwent laparoscopic radical nephrectomy. Four patients whose pathological outcome was not malign kidney tumor have been excluded from the study. Thirty-eight patients (21 males, 16 females; mean age 61 years) who underwent any surgeries in Department of Urology and showed no malignance suspicion in the same time period were included in control group. VHL gen mutations were analyzed preoperatively.

Results: According to 2002 TNM staging, 8 (22%) patients were T1a, 11 (31%) patients were T1b, 3 (8%) patients were T2, 9 (25%) patients were T3a, 3 (8%) patients were T3b, and 2 (6%) patients were T4 stage. Twenty-eight (78%) patients were N0, 5 (14%) patients were N1, and 3 (8%) patients were N2. Five (14%) patients was at M1 stage. Histologically, 18 (50%) patients had clear cell carcinoma, 3 (8.3%) patients had chromofob cell carcinoma, and 3 (8.3%) patients had papillary cell type 1 carcinoma. Genetic analysis showed that 6 individuals had heterozygote change described previously as mutation (Q167Q and V181V linked heterozygote in 2 patients, P61P heterozygote in 2 patients, L129L heterozygote in 1 patient, and P61P heterozygote in 1 patient). None of these changes resulted in the change of aminoacids.

Conclusion: VHL gene mutation was not detected in our study population, which may be result of the genetical characteristics of Turkish population or small sample size. The present study would be a pioneer for future studies on tumor tissue and VHL gene polymorphism in Turkish population.

Similar Articles

Article Info
Published In
Journal Urology Research and Practice
Volume / Issue Volume 37 · Issue 3
Pages 191-197
History
Published Online July 25, 2019
Copyright
Affiliations
Raşit Altıntaş
Bucak Devlet Hastanesi, Üroloji Kliniği, Burdur
Asude Alpman Durmaz
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
Burak Turna
Ege Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İzmir
Hüseyin Onay
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
Ferda Özkınay
Ege Üniversitesi Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, İzmir
İbrahim Kadri Cüreklibatır
Ege Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İzmir
Cite this Article
Altıntaş, R., Durmaz, A. A., Turna, B., Onay, H., Özkınay, F., & Cüreklibatır, İbrahim K. (2019). VHL gene mutation in patients with renal tumors. Urology Research and Practice, 37(3), 191–197. Retrieved from https://urologyresearchandpractice.org/index.php/pub/article/view/2595
Outlines